Pantanetti, P.; Ronconi, V.; Sguanci, M.; Palomares, S.M.; Mancin, S.; Tartaglia, F.C.; Cangelosi, G.; Petrelli, F.
Oral Semaglutide in Type 2 Diabetes: Clinical–Metabolic Outcomes and Quality of Life in Real-World Practice. J. Clin. Med. 2024, 13, 4752.
https://doi.org/10.3390/jcm13164752
AMA Style
Pantanetti P, Ronconi V, Sguanci M, Palomares SM, Mancin S, Tartaglia FC, Cangelosi G, Petrelli F.
Oral Semaglutide in Type 2 Diabetes: Clinical–Metabolic Outcomes and Quality of Life in Real-World Practice. Journal of Clinical Medicine. 2024; 13(16):4752.
https://doi.org/10.3390/jcm13164752
Chicago/Turabian Style
Pantanetti, Paola, Vanessa Ronconi, Marco Sguanci, Sara Morales Palomares, Stefano Mancin, Francesco Carlo Tartaglia, Giovanni Cangelosi, and Fabio Petrelli.
2024. "Oral Semaglutide in Type 2 Diabetes: Clinical–Metabolic Outcomes and Quality of Life in Real-World Practice" Journal of Clinical Medicine 13, no. 16: 4752.
https://doi.org/10.3390/jcm13164752
APA Style
Pantanetti, P., Ronconi, V., Sguanci, M., Palomares, S. M., Mancin, S., Tartaglia, F. C., Cangelosi, G., & Petrelli, F.
(2024). Oral Semaglutide in Type 2 Diabetes: Clinical–Metabolic Outcomes and Quality of Life in Real-World Practice. Journal of Clinical Medicine, 13(16), 4752.
https://doi.org/10.3390/jcm13164752
